Mechanistic Insights of Thyroid Cancer Progression

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Differentiated thyroid cancers (DTCs) originate from MAPK pathway mutations (BRAF, RAS).
• Thyroid cancer progression to poorly differentiated (PDTC) and anaplastic (ATC) forms involves accumulating genetic alterations.
• Identifying key mutations is vital for understanding thyroid cancer evolution and treatment resistance.

Approach:

• Comprehensive review of literature over two decades focusing on bona fide mutations in thyroid cancer progression.
• Analysis of genetic alterations with robust mechanistic data in PDTC/ATC.
• Examination of functional data from in vitro and in vivo models for specific genes and pathways.

Key Points:

• TP53 mutations, PI3K/AKT pathway effectors, TERT promoter mutations, SWI/SNF complex alterations, NF2, and EIF1AX are significantly enriched in aggressive thyroid cancers.
• Mechanistic data supports the role of these genetic alterations in thyroid cancer progression.
• Other genetic changes in aggressive tumors are noted, though mechanistic data may be limited.

Conclusions:

• Preclinical studies are essential for translating genomic insights into clinical applications for thyroid cancer.
• Targeting specific genetic pathways identified in this review holds promise for novel therapeutic strategies.
• Further research into less-understood genetic alterations could uncover new therapeutic targets for advanced thyroid cancers.